| 000 -LEADER |
|---|
| fixed length control field |
04791cam a2200853 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
1266258710 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20220525103634.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220302s2022 nyuaf b 000 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2022001763 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780063210790 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0063210797 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)1266258710 |
| Canceled/invalid control number |
(OCoLC)1252411451 |
| -- |
(OCoLC)1273586219 |
| -- |
(OCoLC)1286848313 |
| -- |
(OCoLC)1291404130 |
| -- |
(OCoLC)1296034824 |
| -- |
(OCoLC)1301513438 |
| 037 ## - SOURCE OF ACQUISITION |
|---|
| Source of stock number/acquisition |
Harpercollins, 53 Glenmaura National Blvd Ste 300, Moosaic, PA, USA, 18507-2132 |
| Note |
SAN 200-2086 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
AJM |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Bourla, Albert, |
| Relator term |
author. |
| 9 (RLIN) |
11162 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Moonshot : |
| Remainder of title |
inside Pfizer's nine-month race to make the impossible possible / |
| Statement of responsibility, etc. |
Dr. Albert Bourla. |
| 246 3# - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
Inside Pfizer's nine-month race to make the impossible possible |
| 246 3# - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
Inside Pfizer's 9-month race to make the impossible possible |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
First edition. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
New York, NY : |
| Name of producer, publisher, distributor, manufacturer |
Harper Business, an imprint of HarperCollinsPublishers, |
| Date of production, publication, distribution, manufacture, or copyright notice |
[2022] |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xix, 216 pages, 8 unnumbered pages of plates : |
| Other physical details |
illustrations (some color) ; |
| Dimensions |
24 cm |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Media type code |
n |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Carrier type code |
nc |
| Source |
rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references (pages [197]-214). |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Preface: Luck never comes to the unprepared -- Business NOT as usual -- What is obvious is not always right -- Thinking big makes the impossible possible -- Lightspeed -- The ultimate joy -- Past, present, future -- Manufacturing, the second miracle -- Equity : easier said than done -- Navigating a political minefield -- A beacon of hope -- The science of trust -- A pro-patient, pro-innovation agenda -- Epilogue -- Acknowledgments -- Appendix: Albert Bourla's "we stand with science" open letter to colleagues. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"The exclusive, first-hand, behind-the-scenes story of how Pfizer raced to create the first Covid-19 vaccine, told by Pfizer's CEO Dr. Albert Bourla"-- |
| Assigning source |
Provided by publisher. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made "the impossible possible"--creating, testing, and manufacturing a safe and effective Covid-19 vaccine that previously would have taken years to develop." -- inside front book jacket flap. |
| 600 10 - SUBJECT ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Bourla, Albert. |
| 9 (RLIN) |
11162 |
| 610 20 - SUBJECT ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Pfizer Inc. |
| 9 (RLIN) |
11163 |
| 610 27 - SUBJECT ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Pfizer Inc. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst00532911 |
| 9 (RLIN) |
11163 |
| 647 #7 - SUBJECT ADDED ENTRY--NAMED EVENT |
|---|
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst02024716 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drug development |
| General subdivision |
History. |
| 9 (RLIN) |
11164 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 (Disease) |
| General subdivision |
Vaccination. |
| 9 (RLIN) |
11165 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Viral vaccines |
| General subdivision |
Biotechnology. |
| 9 (RLIN) |
11166 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Viral vaccines. |
| 9 (RLIN) |
11167 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Vaccines industry. |
| 9 (RLIN) |
11168 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Immunology. |
| 9 (RLIN) |
11192 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biotechnology. |
| 9 (RLIN) |
11193 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 (Disease) |
| General subdivision |
Prevention. |
| 9 (RLIN) |
11194 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 Pandemic, 2020- |
| 9 (RLIN) |
11195 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 vaccines |
| General subdivision |
History. |
| 9 (RLIN) |
11196 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
mRNA vaccines |
| General subdivision |
History. |
| 9 (RLIN) |
11197 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Viral Vaccines |
| 9 (RLIN) |
11167 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Allergy and Immunology |
| 9 (RLIN) |
11198 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biotechnology |
| 9 (RLIN) |
11193 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Médicaments |
| General subdivision |
Développement |
| -- |
Histoire. |
| 9 (RLIN) |
11199 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 |
| General subdivision |
Vaccination. |
| 9 (RLIN) |
11200 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Vaccins antiviraux |
| General subdivision |
Biotechnologie. |
| 9 (RLIN) |
11201 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Vaccins antiviraux. |
| 9 (RLIN) |
11202 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Vaccins |
| General subdivision |
Industrie. |
| 9 (RLIN) |
11203 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Immunologie. |
| 9 (RLIN) |
11204 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biotechnologie. |
| 9 (RLIN) |
11183 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pandémie de COVID-19, 2020- |
| 9 (RLIN) |
11184 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
bioengineering. |
| Source of heading or term |
aat |
| 9 (RLIN) |
11185 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology. |
| Source of heading or term |
bisacsh |
| 9 (RLIN) |
11186 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
MEDICAL / Immunology. |
| Source of heading or term |
bisacsh |
| 9 (RLIN) |
11187 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
BUSINESS & ECONOMICS / Research & Development. |
| Source of heading or term |
bisacsh |
| 9 (RLIN) |
11188 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biotechnology. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst00832729 |
| 9 (RLIN) |
11193 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 (Disease) |
| General subdivision |
Prevention. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst02021842 |
| 9 (RLIN) |
11194 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 (Disease) |
| General subdivision |
Vaccination. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst02021881 |
| 9 (RLIN) |
11165 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drug development. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst00898670 |
| 9 (RLIN) |
11189 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Immunology. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst00968006 |
| 9 (RLIN) |
11192 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Vaccines industry. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst01163593 |
| 9 (RLIN) |
11168 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Viral vaccines. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst01167621 |
| 9 (RLIN) |
11167 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Viral vaccines |
| General subdivision |
Research. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst01167622 |
| 9 (RLIN) |
11190 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 (Disease) |
| Source of heading or term |
sears |
| 9 (RLIN) |
11191 |
| 655 #7 - INDEX TERM--GENRE/FORM |
|---|
| Genre/form data or focus term |
History. |
| Source of term |
fast |
| Authority record control number or standard number |
(OCoLC)fst01411628 |
| 9 (RLIN) |
49 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Online version: |
| Main entry heading |
Bourla, Dr. Albert. |
| Title |
Moonshot |
| Place, publisher, and date of publication |
New York : Harper Business, 2022 |
| International Standard Book Number |
9780063210820 |
| Record control number |
(DLC) 2022001764 |
| 907 ## - LOCAL DATA ELEMENT G, LDG (RLIN) |
|---|
| a |
.b173089355 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Koha item type |
Book |